Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....

Ref: STEX/INTIMATION/2026-27 Date: August 07, 2026 BSE Limited National Stock Exchange of India Limited Department of Corporate Services-Listing Exchange Plaza, Bandra Kurla Complex PJ Towers, Dalal Street Bandra (E) Mumbai- 400051 Mumbai- 400001 Scrip Code- 531146 Symbol- MEDICAMEQ Subject: Intimation under SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 Pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited (“the Company”) is scheduled to be held on Friday, August 14, 2026, at the registered office of the Company situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi – 110019, inter alia, to consider and approve the following businesses: 1. To consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026; 2. To consider and approve the Draft Annual Report of the Company for the financial year 2025-26; 3. To consider and approve the Draft Cost Audit Report of the Company for the financial year 2025-26; 4. To transact any other business with the permission of the Chair. It was informed that pursuant to the Company's Code of Conduct framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and amendments made there under, the trading window for dealing in the shares of the Company is closed for all designated persons of the Company from the July 01, 2026 and will open 48 hours after the said Financial Results are declared to Stock Exchanges. This is for your information and record. Yours faithfully For Medicamen Biotech Limited Parul Choudhary Company Secretary & Compliance Officer ACS: 44157